Sign in
Not yet recruitingPhase 4

Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism

Key facts

Who runs it
Region Midtjylland
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
40 people, planned
Started
1 Feb 2026
Expected to end
31 Jan 2028
Type of study
Interventional
Record updated
20 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Male or female with age between 18 and 80 years
  • A low endogenous PTH production is verified by low plasma levels of intact PTH, necessitating treatment with 1-αhydroxylated vitamin D analogs
  • Stable P-calcium levels 1 month prior to inclusion
  • Stable thyroid function as measured by thyroid stimulating hormone (TSH)
  • Speaks and reads Danish

Who cannot take part

  • Metal implants close to the head, which will interfere with the MRI or pacemaker. The patients will complete a metal scheme
  • Uncontrolled diabetes type 1 or 2
  • Uncontrolled hypertension
  • Clinical suspicion of ongoing alcohol abuse (or alcohol-related dementia)
  • Other organic or psychiatric cause the patients’ symptoms
  • Reduced kidney function (eGFR < 30 mL/min/1.73m2)
  • Claustrophobia
  • Pregnancy
  • Unwillingness to participate
  • Clinical suspicion of major depression (also if treated)
  • Contraindications to contrast-enhanced MRI

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

We would like to compare patients with chronic HypoPT treated with TransCon for a long-time period with chronic HypoPT patients treated with conventional treatment (activated vitamin D analogue and calcium supplements) to investigate whether the effect of HypoPT on QoL, neuropsychiatric indices, brain structures, and capillary blood flow are reversed with PTH treatment. We will apply our contrast-enhanced MRI based method to examine whether differences in brain structure and capillary dysfunction depends on the treatment used.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
20 April 2026